baber/WOPTO huggingface dataset:
Patent NZ-547425-A (NZ)
Title: Improvements in or relating to psychometric testing
Inventor: ANDREWS DION GUY
Filed: 2006-05-24
Abstract: A method of conducting psychometric testing comprises the steps of: a. having a candidate located at an assessment station establish a video link between the assessment station and a remote test supervisor using a video transmitting capable communications device; b. the remote supervisor verifying the identity of the candidate and the integrity of the test environment visually via the video feed received from the video transmitting capable communications device being used by the candidate; c. upon verification, the remote supervisor providing instructions and information to the candidate via the video feed in a standardised manner regarding how to establish and log on to an online testing session; d. following instructions for logging on provided by the remote supervisor, the candidate then logs on via the internet to a remotely hosted testing session; e. upon completion of the testing session the candidate's test responses are referred to an assessor remote from the candidate to interpret the candidate's responses and provide a test report.
Patent NZ-561144-A (NZ)
Title: Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
Inventor: TUCK STEPHEN F
IPC: A61K39/35
Filed: 2006-03-03
Abstract: Provided is a composition comprising a structurally stable conjugate molecule, wherein the conjugate molecule comprises a conjugate partner wherein the conjugate partner is an antigen and a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises a 5'-CG-3' sequence and is less than about 200 base pairs in length, and wherein the composition further comprises a component capable of maintaining the pH of the composition in the range of about 6.0 to about 9.0, and wherein the component is Histidine or Phosphate, wherein the Phosphate, if present, is present in the composition at a concentration of between about 20mM and about 50mM. Further provided are compositions with specific sequences.
Patent NZ-563951-A (NZ)
Title: Anti-alphavbeta6 antibodies
Inventor: VIOLETTE SHEILA M
IPC: A61K47/48
Filed: 2003-12-13
Abstract: Disclosed is a monoclonal antibody that is an alpha v beta6 blocking antibody or an antigen binding fragment thereof that (a) specifically binds to alpha v beta6 and not other alpha v integrins or non specific integrins; (b) inhibits the binding of alpha v beta6 to latency associated peptide (LAP) with an IC50 value lower than that of antibody 10D5 and (c) binds alpha v beta6 in either cation independent manner or a cation dependent manner that does not distinguish between the use of Ca2+/Mg2+ and Mn2+ for cation-dependent binding to soluble alpha v beta6, wherein the antibody is not produced by hybridoma 6.3G9 (ATCC accession number PTA-3649) or by hybridoma 6.8G6 (ATCC accession number PTA-3645). Also disclosed are cells producing said antibodies and uses thereof.
Patent NZ-570596-A (NZ)
Title: Refrigerant composition comprising the three hydrofluorocarbons R134a, R125, and R143a, and the hydrocarbon 2-methylpropane
Inventor: POOLE JOHN EDWARD
IPC: C09K5/04
Filed: 2007-03-05
Abstract: Disclosed is a refrigerant composition consisting essentially of, by weight: R134a (1,1,1,2-tetrafluoroethane): 10-25%, R125 (pentafluoroethane): 30-79.9%, R143a (1,1,1-trifluoroethane): 10-30%, and 2-methylpropane (isobutane): 0.3-4%. The specification also more generally discloses refrigerant compositions consisting of three fluorocarbons and a hydrocarbon as described herein.
Patent NZ-572066-A (NZ)
Title: Container that provides airless and predetermined amount of fluid dispensing without unnecessary pumping
Inventor: KAMISHITA TAIZOU
IPC: A61J1/05
Filed: 2007-04-20
Abstract: A fluid container (2) of having a container body (10) provided with a shoulder member (13') and a sidewall (14) that extends between an upper opening (11) and a lower opening (12) is disclosed. Further, a slide valve (40) and a bottom cover (20) are placed in the container body (10). The slide valve (40) is liquid-tight that is slidable along the inner surface (15) of the sidewall (14) of the container body (10) and forms a fluid holding container space (18) between itself (40) and the sidewall (14) of the container body (10). The bottom cover (20) covers the lower opening (12) of the container body (10). The shoulder member (13') and the slide valve (40) have a shoulder surface (32') and a valve surface (42), respectively, which face to each other, and are tilted at an angle in the range from 5 degrees to 30 degrees relative to a horizontal plane. Accordingly, an airless fluid dispensing system using the fluid container (2) prevents a small amount of air from being trapped in the container body (10) during fluid filling and can dispense a predetermined amount of fluid without unnecessary pumping operation before use.
Patent NZ-575556-A (NZ)
Title: Diesel/gas fuel system including proportioning valve, mixing chamber and overflow tank for unburnt fuel mixture
Inventor: FISHER WILL
IPC: F02M43/00
Filed: 2007-09-21
Abstract: A dual fuel system (10) and a dual fuel system assembly where liquid LPG and diesel are mixed and then distributed via the common rail to the combustion chambers. The dual fuel system includes a fuel tank (43) to store pressurized liquefied gas; a proportioning valve means operatively connected to the fuel tank and adapted to control the flow of the liquefied gas; and a mixing chamber (28) operatively connected to the proportioning valve and adapted to mix a proportioned flow of the liquefied gas and a proportioned flow of diesel to form a liquid fuel mixture. In use, the assembly can provide the liquid fuel mixture to a combustion chamber of the diesel engine. Excess unburnt fuel mixture is collected in an overflow tank (65) and returned to the mixing chamber for combustion in the combustion chamber.
Patent NZ-577637-A (NZ)
Title: Non-nucleoside reverse transcriptase inhibitors
Inventor: ANTHONY NEVILLE J
IPC: A61K31/4192
Filed: 2007-12-06
Abstract: Provided is a non-nucleoside reverse transcriptase inhibitor of Formula (I), being a benzotriazole or benzopyrazole, with defined substituents and wherein Q is -C(R4)=N- or -N=N-. The compounds can be used in prophylaxis or treatment of AIDS due to HIV-1.
Patent NZ-581453-A (NZ)
Title: Milking station wherein the feed container can move from a normal position to emptying position
Inventor: BUCKER HEINRICH
IPC: A01K1/12
Filed: 2008-05-05
Abstract: Disclosed is a device for moving a positioning frame (12) and feed container (6) at a milking station. The device comprises at least one movement unit (10) which interacts with the positioning frame (12) or the feed container (6). The positioning frame (12) and the feed container (6) are connected to each other via at least one connecting element (7). The positioning frame (12) and the feed container (6) can be moved synchronously and the feed container (6) can be moved from a normal position into an emptying position.
Patent NZ-591357-A (NZ)
Title: Roller door drive assembly
Inventor: LEIVENZON JACK
IPC: E06B9/13
Filed: 2011-02-24
Abstract: A roller door drive assembly, suitable for operation of garage doors and like barriers having a door curtain that is wound over two drum wheels to form a door curtain drum is disclosed. The drum wheels are supported on an axle and spaced near edges of the door curtain. The roller door drive assembly includes an electric control circuit, a drive module, and an electric module. The electric module comprises an electric control circuit for transferring electrical power to the electric motor. The drive module for the drive assembly has an electric motor for imparting drive to permit up and down rolling of the roller door curtain, via a drive train. The drive module has external dimensions that will enable the drive module to be operatively fitted within the door curtain drum. The electric module is carried with the drive module so that the electric module will also be operatively fitted within the roller door curtain drum. The drive module has the electric motor positioned so an axis of drive rotation is mutually perpendicular to an axis of rotation of the roller door curtain. The electric motor and the drive train are mounted on a chassis of the drive module, such that, in use, the electric motor will face outwardly of a side of the curtain drum. The drive train includes a crown wheel which engages with a drum wheel and is rotationally driven by rotation of the electric motor to drive the door curtain up and down.
Patent NZ-591970-A (NZ)
Title: Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
Inventor: UMANA PABLO
IPC: A61K38/00
Filed: 2004-01-22
Abstract: Provided is an isolated yeast or mammalian host cell engineered to express at least one nucleic acid encoding a fusion polypeptide having beta(1,4)-N-acetylglucosaminyltransferase III activity or beta(1,4)-galactosyltransferase activity and at least one nucleic acid encoding a polypeptide having mannosidase II activity in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide is selected from the group consisting of a whole antibody molecule, an antibody fragment, and a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin.
Patent NZ-593928-A (NZ)
Title: Electronic control of drug delivery system
Inventor: SEBREE TERRI B
IPC: A61N1/04
Filed: 2009-12-29
Abstract: 593928 Disclosed is a drug delivery device (10) for driving an electrotransport current through an animal body surface. The device (10) includes a patch, a controllable power supply (18) and a controller (16). The patch is comprised of two electrodes (12, 14) and one or more reservoirs (30, 32) that store a therapeutic agent. The one or more reservoirs (30, 32) release the therapeutic agent through the animal body surface when the one or more reservoirs (30, 32) are positioned over the electrodes (12, 14) to form an electrical path for the electrotransport current traveling from one of the electrodes (12, 14) to the other of the electrodes (12, 14). The controllable power supply (18) is configured to apply an output voltage across the animal body surface and drive the electrotransport current through the animal body surface. The controller (16) is configured to drive the electrotransport current through the animal body surface in a predetermined profile. The controller (16) is programmed to determine a dynamic value representative of a target electrotransport current. The dynamic value is determined based on a target electrotransport current, a resistance value of a sense resistor used to detect the electrotransport current flowing between electrodes (12, 14) of the device (10), a value of a bandgap voltage associated with the controller (16) and a fixed voltage value. The controller (16) is arranged to control the controllable power supply (18) at least based on a present value of the electrotransport current and the dynamic value representative of the target electrotransport current.
Patent NZ-594852-A (NZ)
Title: System and methods for automatically accessing a web site on behalf of client
Inventor: AGRAWAL PRASHANT KUMAR
IPC: G06F3/02
Filed: 2010-02-05
Abstract: 594852 Disclosed is a system (100) for performing an automated network-based login procedure on an interactive virtual keypad image (105). The system (100) includes a software agent (110) executable from memory of a processor (109) connected to a network (107) for navigating to a login page (104) and accessing the interactive virtual keypad image (105), and performing an automated login. An automated login support application is executable from the same or a different memory of a processor connected to the network (107). The support application includes at least an image processor, an optical character recognizer, and an image data encoder and decoder. The software agent (110) performs a login at the virtual keypad image (105) based on character (106) image matching and location information acquisition. The location information being within the interactive virtual keypad image (105) for each character (106) of a client's specific set of credential characters included in the image of the interactive virtual keypad image (105).
Patent NZ-596927-A (NZ)
Title: A blind guide contact tip, for contacting a workpiece, which mounts onto a drive probe of a nail gun
Inventor: FRANCIS RYAN L
IPC: B25C1/00
Filed: 2010-06-07
Abstract: 596927 Disclosed is a blind guide work contact tip (10) for mounting to a drive probe (26) of a fastening tool, such as a combustion nailer. The blind guide work contact tip is a one piece attachment which is fitted around the existing drive probe. The blind guide work contact tip includes a body (18) and two wings (12) which extend therefrom forming a channel (16) through which a fastener passes into the workpiece. The body has a work surface (64) with a peak and sloped slides adjacent each side of the peak at approximately 45 degrees. This shape allows for an angled nail placement, such as 45 degrees into a workpiece. The thickness of the body makes up between 55%-65% of the total length of the blind guide work contact tip. The work contact tip also has a flat portion at the peak of the work surface so as to not inhibit face nailing.
Patent NZ-597561-A (NZ)
Title: Plants with modified lignin content and methods for production thereof
Inventor: ZHAO QIAO
IPC: A01H5/00
Filed: 2010-07-12
Abstract: 597561 PLANTS WITH MODIFIED LIGNIN CONTENT AND METHODS FOR PRODUCTION THEREOF Provided is a plant comprising a down-regulated NST transcription factor wherein the plant exhibits reduced lignin content, wherein the plant comprises a mutated NST coding sequence or a DNA molecule capable of expressing a nucleic acid sequence complementary to all or a portion of a NST coding sequence, and wherein the NST coding sequence comprises at least 80% sequence identity to a specified DNA sequence. Further provided are products derived using the transformed plants methods of increasing drought tolerance of plants using the sequences.
Patent NZ-597723-A (NZ)
Title: Synchronized water and production and use thereof
Inventor: JOHANSSON BENNY
IPC: A23L35/00
Filed: 2008-02-13
Abstract: A synchronized water is disclosed, in which all single water molecules at the same time are arranged in an identical way to a stable homogeneous microstructure, wherein said synchronized water in a distilled condition and at atmospheric pressure has a) a density of from 0.997855 to 0.998836 g/ml at 220C, b) a water temperature at the freezing point of from -6.7°C to -8.2°C, c) a melting point of from 0.10C to 0.20C, d) a surface tension of from 72.3 to 72.7 dyn/cm at 220C, and e) a dielectric constant of from 82.4 to 82.6 F/m, as well as a method for preparation thereof and different uses thereof.
Patent NZ-598324-A (NZ)
Title: Aqueous concentrate formulations containing saflufenacil and glyphosate
Inventor: LIEBL REX
IPC: A01N43/54
Filed: 2010-08-26
Abstract: Disclosed herein is an aqueous concentrate formulation for plant protection, comprising the components: a) 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2 H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]sulfonyl]benzamide in the form of its anhydrate; b) N-(phosphonomethyl)glycine in the form of its free acid, in the form of the ammonium salt or a substituted ammonium salt or a mixture thereof; c) at least two different non-ionic surfactants with at least one of them comprising an ethylene oxide polymer moiety or an ethylene oxide/C3-C4-alkylene oxide block copolymer moiety, and d) water; wherein the pH-value of the formulation is below 6.
Patent NZ-600923-A (NZ)
Title: AHAS mutants
Inventor: MCELVER JOHN A
IPC: A01H5/00
Filed: 2008-04-03
Abstract: Disclosed are nucleic acids encoding mutants of the acetohydroxyacid synthase (AHAS) large subunit comprising at least two mutations, for example double and triple mutants, which are useful for producing transgenic or non-transgenic plants with improved levels of tolerance to AHAS-inhibiting herbicides. The invention also provides expression vectors, cells, plants comprising the polynucleotides encoding the AHAS large subunit double and triple mutants, plants comprising two or more AHAS large subunit single mutant polypeptides, and methods for making and using the same.
Patent NZ-601743-A (NZ)
Title: Methods for identifying and isolating cells expressing a polypeptide
Inventor: GURNEY AUSTIN L
IPC: C07K19/00
Filed: 2011-02-11
Abstract: Disclosed is a polypeptide comprising: (i) an extracellular portion that comprises an immunoglobulin heavy chain constant region comprising CH2 and CH3 domains and does not comprise an immunoglobulin heavy chain variable region; and (ii) a non-immunoglobulin transmembrane portion. The polypeptide comprises a sequence as defined in the complete specification. Also disclosed is a method of identifying a cell that produces a heterodimeric molecule of interest comprising: (a) transfecting a cell that expresses a first polypeptide with a polynucleotide that encodes at least one second polypeptide with the first polypeptide comprising (i) an extracellular portion that comprises an immunoglobulin heavy chain constant region comprising CH2 and CH3 domains and does not comprise an immunoglobulin heavy chain variable region; and (ii) a nonimmunoglobulin transmembrane portion with the second polypeptide comprises an immunoglobulin heavy chain; and wherein a heterodimeric molecule comprising the first polypeptide and the second polypeptide is expressed on the surface of the cell; (b) contacting the cell with a detection molecule, wherein the detection molecule binds the heterodimeric molecule; and (c) identifying the cell bound by the detection molecule with the method not being performed within a human being.
Patent NZ-606539-A (NZ)
Title: Use of sigma ligands in opioid-induced hyperalgesia
Inventor: VELA HERNÁNDEZ JOSÉ MIGUEL
IPC: C07D231/22
Filed: 2011-08-02
Abstract: 606539 Disclosed is the use of a sigma ligand having the general formula (I) such as 4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)oxy)ethyl)morpholine (S1RA / E-52862) or a pharmaceutically acceptable salt, stereoisomer, prodrug or solvate thereof, for the manufacture of a medicament for the prevention and/or treatment of opioid induced hyperalgesia associated to opioid therapy. Also disclosed is the use of a combination of at least one sigma ligand as defined above and at least one opioid or opiate compound for simultaneous, separate or sequential administration, for the manufacture of a medicament for the prevention and/or treatment of opioid-induced hyperalgesia associated to opioid therapy.
Patent NZ-612299-A (NZ)
Title: Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
Inventor: STARZL TIMOTHY W
IPC: A61K39/395
Filed: 2011-11-21
Abstract: Discloses a pharmaceutical composition comprising for the treatment of diarrhea: a) an effective amount of at least one specific binding molecule, or fragment thereof, wherein the specific binding molecules are polyclonal immunoglobulin Y (IgY) antibodies prepared in eggs of hens inoculated with one or a mixture of pathogenic components, wherein the (IgY) antibodies comprise a mixture of IgY specific for antigens derived from Escherichia coli, rotavirus, and coronavirus pathogens, pathogen related toxins, and/or pathogen related adhesion elements; and, b) a carrier matrix comprising a matrix obtained from, isolated from, or derived from, bovine colostrum, and that comprises at least two components obtained from a nonhuman animal selected from the group consisting of enzymes, lactoferrin, transferrin, nonspecific immunoglobulins, cytokines, white blood cells, complement components, interferons, and fibronectin, wherein the mixture of IgY antibodies is in an effective amount for the treatment or prevention of undifferentiated diarrhea, traveler’s diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, or for gastrointestinal flora management in a non-neonate human.
Patent NZ-624072-A (NZ)
Title: Combination therapies using anti- pseudomonas psl and pcrv binding molecules
Inventor: RAINEY GODFREY
IPC: C07K16/12
Filed: 2012-11-06
Abstract: Disclosed are bispecific antibodies comprising a binding domain that binds to Pseudomonas Psl and a binding domain that binds to Pseudomonas PcrV.
Patent NZ-624534-A (NZ)
Title: Anti-fgfr2 antibodies and uses thereof
Inventor: LINDEN LARS
IPC: C07K16/30
Filed: 2012-11-22
Abstract: Disclosed is an isolated antibody or antigen-binding fragment thereof specifically binding to the extracellular N-terminal epitope (RPSFSLVEDTTLEPE) of FGFR2 as presented by SEQ ID NO:63. Also disclosed is the use of said antibody or antigen-binding fragment in the manufacture of a medicament for the treatment of cancer.
Patent NZ-625674-A (NZ)
Title: Retaining apparatus and method of use
Inventor: KERR DION
IPC: E04G25/00
Filed: 2011-12-06
Abstract: A reusable system (100) for creating formwork for concrete foundations is disclosed. The system consists of a retaining rod (3) and an extruded board (5) used in conjunction with the retaining rod. The retaining rod is driven into the ground and the boards are retained in position on the member by a sleeve (4) clamped to the rod and the boards. An arm (7) may also be clamped to the rod or sleeve which is used to help stabilise the retaining rod. Multiple boards may be stacked to increase the height of the formwork and also connected end to end to increase the length.
Patent NZ-713035-A (NZ)
Title: Therapeutic compositions for the treatment and prevention of colon cancer
Inventor: KERRY PAUL
IPC: A61P35/00
Filed: 2013-04-05
Abstract: The disclosure relates to use of a compound of formula (IA) or (IIA) and optionally with at least one additional therapeutic agent, in the manufacture of a composition for treating or preventing colon cancer in a subject, wherein the variables are as defined in the specification. Also described are pharmaceutical compositions comprising compounds including 5-phenylpenta-2,4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. The composition may include as additional therapeutic agent selected from an anti-tumour agent, preferably the anti-tumour agent is selected from an anti-tumour food factor, a chemotherapeutic agent, or an immunotherapeutic agent. These pharmaceutical compositions are also useful in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers.
Patent NZ-716568-A (NZ)
Title: Inhibitors of the farnesoid x receptor and uses in medicine
Inventor: GONZALEZ FRANK J
IPC: C07J41/00
Filed: 2014-08-01
Abstract: Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid X receptor in a mammal, and a method of treating or preventing obesity in a mammal.